Fintel reports that on October 6, 2025, LUCID CAPITAL MARKETS initiated coverage of Cassava Sciences (NasdaqCM:SAVA) with a ...

Lucid Capital initiated coverage of Cassava Sciences (SAVA) with a Buy rating and $8 price target Cassava is developing simufilam to treat a ...

Cassava shares are down 34c, or 12%, to $2.46 in pre-market trading after resuming following a halt for news pending. Published first on TheFly – the ultimate source for real-time, market-moving ...

Cassava Sciences (NASDAQ:SAVA) boss Richard Barry is putting his own skin in the game. The CEO just snapped up 237,941 shares ...

Cassava Sciences (SAVA) has entered into an agreement with Yale University for a license to intellectual property rights, including an exclusive license to an issued US method of treatment patent for ...

Charles Schwab Investment Management Inc. grew its position in Cassava Sciences, Inc. (NASDAQ:SAVA – Free Report) by 13.0% during the 1st quarter, according to the company in its most recent ...

Cassava Science provided a business update. In November 2024, Cassava reported that the topline results from the Phase 3 RETHINK-ALZ study evaluating simufilam as a potential treatment for patients ...

Cassava Sciences, Inc. has announced the expected release of topline data from its Phase 3 REFOCUS-ALZ study on simufilam for mild-to-moderate Alzheimer's disease, anticipated in late Q1 or early Q2 ...

Cassava and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On November 25, 2024, the Company disclosed ...

NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the ...

NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during ...

NEW YORK (Reuters) -The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who expressed doubts about its experimental, soon ...